2026-04-19T19:22:20Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2223402025-12-04T19:16:36Zcom_2072_1057col_2072_478858col_2072_478916col_2072_478917

urn:hdl:2445/222340 KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis Otero Mateo, Marc Estrany Jr, Francesc Arcas Márquez, Sabrina Moya Borrego, Laura Castellano, Giancarlo Castany Roma, Miquel Alemany Bonastre, Ramon Fillat i Fonts, Cristina Càncer de pàncrees Terapèutica Pancreas cancer Therapeutics Oncolytic adenoviral therapy is a promising approach for pancreatic cancer treatment. However, the limited capacity of murine cells to produce infectious viral progeny precludes the full evaluation of the virotherapy in a suitable immunocompetent mouse model. Here, we report that the murine KPC-I cell line, established from pancreatic tumors developed in to adenoviral replication and generates a progeny of infective virions similar to those from infected human A549 cells. A comparative study with the semipermissive murine CMT64.6 cells reveals that adenoviral infection of KPC-I cells substantially increases the release of infective particles, with a correlating enhanced susceptibility to adenovirus-induced autophagy. Remarkably, systemic delivery of the oncolytic adenovirus AdNuPARE1A in athymic mice bearing KPC-I tumors results in significant inhibition of tumor growth. Moreover, KPC-I tumors in immunocompetent mice with intratumoral administration of AdNuPARE1A or ICOVIR15kDelE3 display significant antitumoral effects, with evidence of adenoviral replication. Collectively, our data show that KPC-I cells are permissive to human oncolytic adenovirus replication, rendering KPC-I syngeneic tumors an interesting model to evaluate the multifaceted antitumor activities of oncolytic adenovirus. 2025-07-17T12:25:05Z 2025-07-17T12:25:05Z 2025-03-01 2025-05-16T11:55:20Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1016/j.omton.2024.200928 Molecular Therapy Oncology, 2025, vol. 33, num. 1, 200928 https://doi.org/10.1016/j.omton.2024.200928 cc-by-nc-nd (c) Otero Mateo, Marc et al., 2025 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess Elsevier BV Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))